Author:
Campbell Katie M.,Amouzgar Meelad,Pfeiffer Shannon M.,Howes Timothy R.,Medina Egmidio,Travers Michael,Steiner Gabriela,Weber Jeffrey S.,Wolchok Jedd D.,Larkin James,Hodi F. Stephen,Boffo Silvia,Salvador Lisa,Tenney Daniel,Tang Tracy,Thompson Marshall A.,Spencer Christine N.,Wells Daniel K.,Ribas Antoni
Reference70 articles.
1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010
2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N. Engl. J. Med.,2015
3. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N. Engl. J. Med.,2019
4. Center for Drug Evaluation, and Research FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Advanced Solid Tumors. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors.
5. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors;Marcus;Clin. Cancer Res.,2021
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献